Hypusination of eukaryotic initiation factor 5A(eIF5A): A novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach

Blood

Volumn 109, Issue 4, 2007, Pages 1701-1711

  Balabanov, Stefan ^a,b   Gontarewicz, Artur ^a   Ziegler, Patrick ^b   Hartmann, Ulrike ^b   Kammer, Winfried ^c   Copland, Mhairi ^d   Brassat, Ute ^a   Priemer, Martin ^c   Hauber, Ilona ^e   Wilhelm, Thomas ^c   Schwarz, Gerold ^c   Kanz, Lothar ^b   Bokemeyer, Carsten ^a   Hauber, Joachim ^e   Holyoake, Tessa L ^d   Nordheim, Alfred ^c   Brümmendorf, Tim H ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD34 ANTIGEN; CICLOPIROX; GC 7; HYPUSINATION INHIBITOR; IMATINIB; INITIATION FACTOR 5A; ISOPROTEIN; N 1 GUANYL 1,7 DIAMINOHEPTANE; PROTEIN INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; CELL CYCLE; CELL LABELING; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DOWN REGULATION; DRUG POTENCY; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; RNA INTERFERENCE;

EID: 33846939244     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-03-037648     Document Type: Article

References (53)

1. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100-104
2. O'Brien SG, Guilhot F, Larson RA, et al. imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
3. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432.
4. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
5. Sawyers CL, Hochhaus A, Feldman E, et al. imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539.
6. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401.
7. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129-141.
8. Steelman LS, Pohnert SC, Shelton JG, et al. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 2004;18:189-218.
9. Ohmine K, Nagai T, Tarumoto T, et al. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR. Stem Cells. 2003;21:315-321.
10. Advani AS, Dressman HK, Quiroz M, Taylor GA, Pendergast AM. Elevated expression of a subset of interferon inducible genes in primary bone marrow cells expressing p185 Bcr-Abl versus p210 Bcr-Abl by DNA microarray analysis. Leuk Res. 2004;28:285-294.
11. Nowicki MO, Pawlowski P, Fischer T, et al. Chronic myelogenous leukemia molecular signature. Oncogene. 2003;22:3952-3963.
12. Bruchova H, Borovanova T, Klamova H, Brdicka R. Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea. Leuk Lymphoma. 2002;43:1289-1295.
13. Unwin RD, Sternberg DW, Lu Y, et al. Global effects of BCR/ABL and TEL/PDGFRβ expression on the proteome and phosphoproteome: identification of the rho pathway as a target of BCR/ABL. J Biol Chem. 2005;280:6316-6326.
14. Smith DL, Evans CA, Pierce A, Gaskell SJ, Whetton AD. Changes in the proteome associated with the action of Bcr-Abl tyrosine kinase are not related to transcriptional regulation. Mol Cell Proteomics. 2002;1:876-884.
15. Srinivas PR, Verma M, Zhao Y, Srivastava S. Proteomics for cancer biomarker discovery. Clin Chem. 2002;48:1160-1169.
16. Westermeier R, Postel W, Weser J, Gorg A. High-resolution two-dimensional electrophoresis with isoelectric focusing in immobilized pH gradients. J Biochem Biophys Methods. 1983;8:321-330.
17. Cristea IM, Gaskell SJ, Whetton AD. Proteomics techniques and their application to hematology. Blood. 2004;103:3624-3634.
18. Balabanov S, Zimmermann U, Protzel C, et al. Tumour-related enzyme alterations in the clear cell type of human renal cell carcinoma identified by two-dimensional gel electrophoresis. Eur J Biochem. 2001;268:5977-5980.
19. Park MH, Wolff EC, Smit-McBride Z, Hershey JW, Folk JE. Comparison of the activities of variant forms of eIF-4D. The requirement for hypusine or deoxyhypusine. J Biol Chem. 1991;266:7988-7994.
20. Park MH, Wolff EC, Lee YB, Folk JE. Antiproliferative effects of inhibitors of deoxyhypusine synthase: inhibition of growth of Chinese hamster ovary cells by guanyl diamines. J Biol Chem. 1994;269:27827-27832.
21. Clement PM, Hanauske-Abel HM, Wolff EC, Kleinman HK, Park MH. The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro. Int J Cancer. 2002;100:491-498.
22. Bartolovic K, Balabanov S, Hartmann U, et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood. 2004;103:523-529.
23. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
24. Gorg A, Obermaier C, Boguth G, et al. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis. 2000;21:1037-1053.
25. Shevchenko A, Jensen ON, Podtelejnikov AV, et al. Linking genome and proteome by mass spectrometry: large-scale identification of yeast proteins from two dimensional gels. Proc Natl Acad Sci U S A. 1996;93:14440-14445.
26. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 1999;20:3551-3567.
27. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72:8463-8471.
28. Beyer WR, Westphal M, Ostertag W, von Laer D. Oncoretrovirus and lentivirus vectors pseudo-typed with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J Virol. 2002;76:1488-1495.
29. Twentyman PR, Fox NE, Rees JK. Chemosensitivity testing of fresh leukaemia cells using the MTT colorimetric assay. Br J Haematol. 1989;71:19-24.
30. Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem. 1981;115:207-216.
31. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
32. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991;139:271-279.
33. Brummendorf TH, Dragowska W, Zijlmans JMJM, Thornbury G, Lansdorp PM. Asymmetric cell divisions sustain long-term hematopoiesis from single-sorted human fetal liver cells. J Exp Med. 1998;188:1117-1124.
34. Jordan CT, Yamasaki G, Minamoto D. High-resolution cell cycle analysis of defined phenotypic subsets within primitive human hematopoietic cell populations. Exp Hematol. 1996;24:1347-1355.
35. - cell production in vitro. Br J Haematol. 1997;98:528-539.
36. Gordon ED, Mora R, Meredith SC, Lee C, Lindquist SL. Eukaryotic initiation factor 4D, the hypusine-containing protein, is conserved among eukaryotes. J Biol Chem. 1987;262:16585-16589.
37. Park MH, Chung SI, Cooper HL, Folk JE. The mammalian hypusine-containing protein, eukaryotic initiation factor 4D: structural homology of this protein from several species. J Biol Chem. 1984;259:4563-4565.
38. Caraglia M, Budillon A, Vitale G, et al. Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation. Eur J Biochem. 2000;267:3919-3936.
39. Park MH, Wolff EC, Folk JE. Hypusine: its posttranslational formation in eukaryotic initiation factor 5A and its potential role in cellular regulation. Biofactors. 1993;4:95-104.
40. Park MH, Wolff EC, Folk JE. Is hypusine essential for eukaryotic cell proliferation? Trends Biochem Sci. 1993;18:475-479.
41. Singh US, Li Q, Cerione R. Identification of the eukaryotic initiation factor 5A as a retinoic acid-stimulated cellular binding partner for tissue transglutaminase II. J Biol Chem. 1998;273:1946-1950.
42. Kruse M, Rosorius O, Kratzer F, et al. Inhibition of CD83 cell surface expression during dendritic cell maturation by interference with nuclear export of CD83 mRNA. J Exp Med. 2000;191:1581-1590.
43. Guan XY, Fung JM, Ma NF, et al. Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer Res. 2004;64:4197-4200.
44. Bevec D, Jaksche H, Oft M, et al. Inhibition of HIV-1 replication in lymphocytes by mutants of the Rev cofactor eIF-5A. Science. 1996;271:1858-1860.
45. Hofmann W, Reichart B, Ewald A, et al. Cofactor requirements for nuclear export of Rev response element (RRE)- and constitutive transport element (CTE)-containing retroviral RNAs: an unexpected role for actin. J Cell Biol. 2001;152:895-910.
46. Hauber I, Bevec D, Heukeshoven J, et al. Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy. J Clin Invest. 2005;115:76-85.
47. Li AL, Li HY, Jin BF, et al. A novel eIF5A complex functions as a regulator of p53 and p53-dependent apoptosis. J Biol Chem. 2004;279:49251-49258.
48. Caraglia M, Passeggio A, Beninati S, et al. Interferon alpha2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells. Biochem J. 1997;324(part 3):737-741.
49. Caraglia M, Marra M, Giuberti G, et al. The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells. J Biochem (Tokyo). 2003;133:757-765.
50. Caraglia M, Tagliaferri P, Budillon A, Abbruzzese A. Posttranslational modifications of eukaryotic initiation factor-5A (eIF-5A) as a new target for anti-cancer therapy. Adv Exp Med Biol. 1999;472:187-198.
51. Topaly J, Zeller WJ, Fruehauf S. Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. Br J Haematol. 2002;119:3-14.
52. Gardembas M, Rousselot P, Tulliez M, et al. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood. 2003;102:4298-4305.
53. Mann M, Ong SE, Gronborg M, et al. Analysis of protein phosphorylation using mass spectrometry: deciphering the phosphoproteome. Trends Biotechnol. 2002;20:261-268.